DDX53 and neoplasm: Intriguingly, while chemoradiation alone failed to sensitize the CT26 tumor‐bearing model to anti‐PD1 immunotherapy, acipimox dramatically enhanced the sensitivity of these tumors to the combination of chemoradiation and anti‐PD1 therapy (Figure S7K–M, Supporting Information).